MIRVETUXIMAB SORAVTANSINE (IMGN-853) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/ Collaborator
PH2 Study of IMGN853 vs Investigator’s Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube CancerNCT02631876IIImmunoGen, Inc.
Study of IMGN853 in Comb. With Bevacizumab, Carboplatin, PLD or Pembrolizumab in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial CancerNCT02606305IIImmunoGen, Inc.
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors (IMGN-0401)NCT01609556IImmunoGen, Inc.